May 19, 2010: Allostera Pharma Inc. Appoints Christopher Henney as Chairman of its Board Of Directors (PDF): MONTRÉAL, QUÉBEC, CANADA. MAY 19, 2010 -- Allostera Pharma Inc. today announced it has appointed Christopher Henney, PhD, as Chairman of its Board of Directors. Dr. Henney is the co-founder of Immunex (acquired by Amgen [Nasdaq:AMGN] in 2002), Icos (acquired by Lilly [NYSE:LLY] in 2007) and Dendreon [Nasdaq:DNDN].

July 8, 2009: Allostera Pharma Inc. Closes $17M (CAD) Series A Financing (PDF): MONTRÉAL, QUÉBEC, CANADA. JULY 7, 2009 -- Allostera Pharma Inc. today announced it has secured a Series A financing of $17 million (Canadian dollars). Four venture funds participated: iNovia Capital, Genesys Capital, BDC Venture Capital with GO Capital, and Fonds Bio-Innovation s.e.c. The proceeds of the financing will be used for the development of Allosteramers™, a new class of drugs developed by Allostera scientists that are both highly specific for their targets and designed to be orally bioavailable. Additionally with these proceeds, Allostera plans to complete preclinical studies and begin human clinical testing of its lead Allosteramer™, APG2305, a novel drug candidate for treating autoimmune diseases like psoriasis that has demonstrated oral activity in animals. Read more - download full press release...